Champions Oncology (CSBR) Stock Price, News & Analysis

Champions Oncology, Inc. (NASDAQ: CSBR) is a translational oncology research organization and global preclinical and clinical research services provider focused on supporting oncology drug discovery and development. According to the company’s disclosures and recent press releases, Champions Oncology offers end-to-end oncology R&D solutions and data platforms to biopharma organizations, with operations classified under biological product (except diagnostic) manufacturing in the manufacturing sector.

The company’s business is centered on oncology research services and data. In its Polygon description, Champions Oncology states that it develops and sells technology solutions and products to personalize the development and use of oncology drugs, operating through Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS business assists physicians in developing personalized treatment options for cancer patients using tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and can provide studies or license tumors for use in studies. The company notes that its revenue is primarily derived from research services.

Oncology research services and model platforms

In multiple recent news releases, Champions Oncology describes itself as a provider of preclinical and clinical research services that enable oncology R&D programs worldwide. The company highlights that it maintains what it describes as the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models. These models are used in proprietary in vivo and ex vivo platforms to generate data intended to reflect clinically relevant tumor biology.

Champions Oncology also refers to a large portfolio of bioanalytical platforms, a data platform and analytics capabilities. These elements are positioned as tools that help biopharma organizations advance preclinical and clinical oncology drug discovery and development programs by generating and analyzing multi-dimensional data from its model systems and studies.

Data platform and multi-omic datasets

Recent company communications emphasize an emerging data platform as a distinct growth area. Champions Oncology reports that it is investing in sequencing and related activities to advance a data licensing platform and that it has generated data license revenue alongside its services revenue. In a news release describing a collaboration with Turbine, the company states that it has developed comprehensively annotated, clinically relevant multi-omic datasets, including deeply characterized samples paired with in vivo experimental results and clinical outcome data from the same patients. These datasets are used in conjunction with its model systems to support in silico and traditional research workflows.

The company’s management commentary in earnings releases describes this data platform as a separate but complementary growth engine to its core services business. Champions Oncology notes that as the data business scales, it expects it to contribute to long-term growth while introducing additional variability in shorter reporting periods.

Radiopharmaceutical and radiotherapeutic capabilities

Champions Oncology has also disclosed the development of radiopharmaceutical research capabilities. In 2025, the company announced that it obtained a radioactive materials license to conduct preclinical studies using radioactive materials in-house. It subsequently announced the full commercial launch of a radiopharmaceutical services platform, following completion of radiochemistry infrastructure and the screening of more than thirty PDX models in collaboration with pharmaceutical and biotech partners.

According to these announcements, the company’s radiopharmaceutical platform offers integrated workflows that combine in vitro, ex vivo biodistribution and therapeutic efficacy studies across a range of isotopes. Champions Oncology states that its updated radioactive materials license covers ten isotopes, including Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211, Tb-161, Cu-64 and Zr-89. The company indicates that these capabilities support studies in areas such as radioligand therapy, antibody radionuclide conjugates and theranostic approaches, integrated with its PDX tumor model bank.

Financial reporting and business mix

Champions Oncology reports its results as oncology revenue and discusses oncology services profit and oncology services margin as non-GAAP metrics. In its earnings releases for fiscal 2025 and fiscal 2026 periods, the company distinguishes between service revenue and data license revenue within total oncology revenue, and it notes that research services and data licensing both contribute to its oncology revenue stream. Management commentary emphasizes oncology services margins and the impact of operational efficiencies, outsourced lab services and the scaling of in-house capabilities such as radiolabeling work.

The company has also highlighted the contribution of data license revenue to its overall revenue stream in its fiscal year 2025 results, describing data license revenue as part of its oncology revenue and noting that high-margin data revenue contributed to margin improvements at the annual level. Champions Oncology reports using non-GAAP measures such as adjusted EBITDA and adjusted EPS to evaluate its operating performance, while providing reconciliations to GAAP measures.

Corporate structure and governance

Champions Oncology is incorporated in Delaware and its common stock, with a par value of $0.001 per share, trades on The Nasdaq Stock Market LLC under the symbol CSBR, as disclosed in its SEC filings. The company files periodic reports, proxy statements and current reports on Form 8-K with the U.S. Securities and Exchange Commission. A definitive proxy statement filed in 2025 describes an annual meeting of stockholders, the election of directors, ratification of the independent registered public accounting firm and an advisory vote on executive compensation.

In 2025, the company reported leadership changes through both press releases and Form 8-K filings, including the appointment of a new Chief Executive Officer and the transition of the prior CEO to an executive chairman role. These filings also describe related employment arrangements and equity awards. Champions Oncology’s proxy materials and 8-K filings provide additional detail on its board composition, executive compensation and governance practices.

Role in oncology R&D ecosystem

Across its public communications, Champions Oncology characterizes itself as a partner to biopharma organizations engaged in oncology drug discovery and development. The company positions its PDX and primary hematological malignancy models, bioanalytical platforms, radiopharmaceutical capabilities and data platform as tools that help drug developers generate translational data, evaluate therapeutic candidates and support decision-making in preclinical and clinical programs. Its historical POS and TOS segments, along with its more recent emphasis on data licensing and radiopharmaceutical services, reflect a focus on oncology research services and related data offerings.